SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that the company will participate in four
upcoming investor conferences.
Details of the company's participation are as follows:
- Citi's 16th Annual Biopharma Virtual
Conference
Details: Viking management will
participate in 1-on-1 meetings
Conference Dates: September 8-10, 2021
Format: Virtual conference
- H.C. Wainwright 23rd Annual Global Investment
Conference
Details: Viking management will deliver a
corporate presentation and participate in 1-on-1
meetings
Conference Dates: September 13-15,
2021
Presentation Timing: Available online at 7:00 a.m. Eastern on Monday, September 13, 2021
Format: Virtual conference
- Oppenheimer Fall Healthcare Life Sciences & MedTech
Summit
Details: Viking management will deliver a
corporate presentation and participate in 1-on-1
meetings
Conference Dates: September 20-23, 2021
Presentation Timing: Tuesday, September 21,
2021 at 2:55 p.m.
Eastern
Format: Virtual conference, webcast available
- Cantor Fitzgerald Virtual Global Healthcare
Conference
Details: Viking management will
deliver a corporate presentation and participate in 1-on-1
meetings
Conference Dates: September 27-30,
2021
Presentation Timing: Thursday, September 30,
2021 at 2:00 p.m.
Eastern
Format: Virtual conference
A webcast of the Oppenheimer presentation may be accessed via a
link on the Viking Therapeutics website in the Investors &
Media section under Webcasts. Additionally, a replay of
the webcast will be available on the Viking website following the
conferences.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel, orally available,
first-in-class or best-in-class therapies for the treatment of
metabolic and endocrine disorders. Viking's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, which is currently being evaluated in a
Phase 2b study for the treatment of biopsy-confirmed
non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase
2a trial for the treatment of non-alcoholic fatty liver disease
(NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the potential treatment of X-linked
adrenoleukodystrophy (X-ALD). VK0214 is currently being
evaluated in a Phase 1b clinical
trial in patients with the adrenomyeloneuropathy (AMN) form of
X-ALD. The company holds exclusive worldwide rights to a
portfolio of five therapeutic programs, including those noted
above, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com. Follow Viking on Twitter
@Viking_VKTX.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-301368690.html
SOURCE Viking Therapeutics, Inc.